Abstract: Chimeric antigen receptors (CARs) are disclosed, along with nucleic acids and vectors encoding, and recombinant cells comprising such CARs and therapeutic compositions containing any of the foregoing. The CARs may comprise mutations that alter CAR expression, cytotoxicity, or cytokine production. Also provided are methods for using recombinant cells comprising these CARs for immunotherapy, e.g., in treating cancer by the administration of a therapeutically effective amount of one or more of the CAR polypeptides, nucleic acids, vectors, and/or immune cells, e.g., human CAR T cells, described herein optionally in combination with other immune and cancer treatments.

Abstract: The present disclosure generally relates to novel chimeric antigen receptors (“CARs”), modified regulatory T cells (“Tregs”) expressing such CARs and/or Tregs which are engineered to express neurodegenerative disease modifying molecules, e.g., which express molecules which prevent oxidative/inflammatory activity, or which promote neuronal growth/survival such as nerve growth factors or non-classical neurotrophic factors. The present disclosure also generally relates to compositions containing such modified Tregs, and methods of use thereof as therapeutics, in particular for treating and preventing neurodegenerative diseases and symptoms associated with therewith, and/or for slowing the onset of such neurodegenerative diseases, particularly in persons at risk because of genetic factors or in persons exhibiting early signs of developing such a neurodegenerative disease.

Abstract: The present disclosure generally relates to novel chimeric antigen receptors (“CARs”), modified regulatory T cells (“Tregs”) expressing such CARs and/or Tregs which are engineered to express neurodegenerative disease modifying molecules, e.g., which express molecules which prevent oxidative/inflammatory activity, or which promote neuronal growth/survival such as nerve growth factors or non-classical neurotrophic factors. The present disclosure also generally relates to compositions containing such modified Tregs, and methods of use thereof as therapeutics, in particular for treating and preventing neurodegenerative diseases and symptoms associated with therewith, and/or for slowing the onset of such neurodegenerative diseases, particularly in persons at risk because of genetic factors or in persons exhibiting early signs of developing such a neurodegenerative disease.

Abstract: An industrial dryer for drying industrial materials, such as sludge, salt water, brines and the like. A transition plate which is slotted in a manner to cause hot gases flowing toward and through the slots to be immediately transformed into a free standing vortex on the downstream side of the transition plate. The vortex operates on the wet materials and the hot gases. Structure is provided to collect the water vapor created by the drying action. In a first embodiment, hot gases are created by the operation of a blower which directs air under pressure through a heater, then into and through the slotted transition plate. In a second embodiment, a resonating engine is used as a source of hot gases.

Abstract: Apparatus and a method for handling a gas and a liquid in a manner to cause a specific interaction between them. The gas is placed into circulation to cause it to make a liquid circulate in a vortex fashion to present a liquid curtain. The gas is then passed through the liquid curtain by angled vanes to cause the interaction between the two fluids, such as the heating of the liquid, scrubbing of the gas, adding a chemical to the liquid and the like. The vanes are spaced apart and project inwardly from the inner periphery of an annular support so that the circulating liquid readily moves into the spaces between the vanes to create the liquid curtain. A number of embodiments of the invention are disclosed.